Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov100310.25208/vdv1003ArticlesСтатьиExperience of using peroral cosmetic products from the Emolium series in the complex therapy of children suffering from atopic dermatitisОпыт применения наружных средств косметической линии Эмолиум в комплексной терапии детей, больных атопическим дерматитомTEKUCHEVAL VТЕКУЧЕВАЛ В

старший научный сотрудник отделения детской дерматологии, к.м.н; ФГУ «ГНЦДК Минздравсоцразвития России»

detstvo@cnikvi.ruZNAMENSKAYAL FЗНАМЕНСКАЯЛ Ф

заведующая отделом дерматологии, к.м.н; ФГУ «ГНЦДК Минздравсоцразвития России»

ФГУ «ГНЦДК Минздравсоцразвития России»15042011872NO2 (2011)№2 (2011)717711032020Copyright ©; 2011, TEKUCHEVA L.V., ZNAMENSKAYA L.F.Copyright ©; 2011, ТЕКУЧЕВА Л.В., ЗНАМЕНСКАЯ Л.Ф.2011TEKUCHEVA L.V., ZNAMENSKAYA L.F.ТЕКУЧЕВА Л.В., ЗНАМЕНСКАЯ Л.Ф.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/1003

The authors summarized the current data on the function of the epidermal barrier, mechanisms of its affection and its role in the development of atopic dermatitis. They present the results confirming the efficacy of complex administration of basic skin care products in the therapy of children suffering from atopic dermatitis. Basic skin care products were cosmetic products from the Emolium series in the form of cream and emulsion as well as skin hygiene products (bath emulsion, cream washing gel).

Обобщены современные данные о функции эпидермального барьера, механизмах его нарушения и роли в развитии атопического дерматита. Представлены результаты, подтверждающие эффективность комплексного применения средств базового ухода в терапии детей, больных атопическим дерматитом. Для базового ухода использовались косметические средства линии Эмолиум в форме крема, эмульсии, а также средства гигиены кожи (эмульсия для ванн, кремовый гель для умывания).

atopic dermatitisepidermal barrieremollientsEmolium cosmetic productstransepidermal water lossатопический дерматитэпидермальный барьерэмолентыкосметические средства Эмолиумтрансэпидермальная потеря водыBieber T. Atopic dermatitis. N Engl J Med 2008; 358: 1483-1494.Simpson C.R., Newton J., Hippisley-Cox J. et al. Trends in the epidemiology and prescribing of medication for eczema in England. J R Soc Med 2009; 102: 108-117.Levy R.M., Gelfand J.M., Yan A.C. The epidemiology of atopic dermatitis. Clin Dermatol 2003; 21: 109-115.Schmitt J., Bauer A., Meurer M. Atopic eczema in adulthood. Hautarzt 2008; 59: 841-850.Hanifin J.M., Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Suppl) 1980; 92: 44-47.Akdis C., Akdis M., Bieber T. et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology / American Academy of Allergy, Asthma and Immunology / PRACTALL Consensus Report. J Allergy Clin Immunol 2006;118:152-169.Novak N., Bieber T., Leung D. Immune mechanisms leading to atopic dermamitis. J Allegy Clin Immunol 2003; 112: 128-139.Cork M.J., Danby S.G., Vasilopoulos Y. et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009; 129: 1892-1908.Leung D.Y. Our evolving understanding of the functional role of filaggrin in atopic dermatitis. J Allergy Clin Immunol 2009; 124: 494-495.Elias P. Stratum corneum defensive functions: an integrated view. J Invest Dermatol 2005; 125: 183-200.Palmer C.N., Irvine A.D., Terron-Kwiatkowski A. et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-446.Sandilands A., O'Regan G.M., Liao H. et al. Prevalent and rare mutations in the gene encoding filaggrin cause ichthyosis vulgaris and predispose individuals to atopic dermatitis. J Invest Dermatol 2006; 126: 1770-1775.Palmer C.N., Ismail T., Lee S.P. et al. Filaggrin null mutations are associated with increased asthma severity in children and young adults. J Allergy Clin Immunol 2007; 120: 64-68.Barker J.N., Palmer C.N., Zhao Y. et al. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. J Invest Dermatol 2007; 127: 504-507.Stemmler S., Parwez Q., Petrasch-Parwez E. et al. Two common loss-of-function mutations within the filaggrin gene predispose for early onset of atopic dermatitis J. Invest. Dermatol. 2007: 127: 722-724.Weidinger S., Illig T., Baurecht H., Irvine A.D., Rodriguez E., Diaz- Lacava A. et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations J Allergy Clin Immunol 2006; 118: 214-219.Irvine A. D. Fleshing out filaggrin phenotypes. J Invest Dermatol 2007; 127: 504-507.Brown S. J., Sandilands A., Zhao Y. et al. Prevalent and low frequency null mutations in the filaggrin gene are associated with early-onset and persistent atopic eczema J Invest Dermatol 2008; 128: 1591-1594.Marenholz I., Nickel R., Ruschendorf F. et al. Filaggrin loss-of- function mutations predispose to phenotypes involved in the atopic march. J Allergy Clin Immunol 2006; 118: 866-871.Ruether A., Stoll M., Schwarz T. et al. Filaggrin loss-of-function variant contributes to atopic dermatitis risk in the population of Northern Germany. Br J Dermatol 2006; 155: 1093-1094.Akiyama M. FLG mutations in ichthyosis vulgaris and atopic eczema: spectrum of mutations and population genetics British Journal of Dermatology 2010; 162: 472-477.Zhang X., Liu S., Chen X. et al. Novel and Recurrent Mutations in the Filaggrin Gene in Chinese Patients with Ichthyosis Vulgaris British Journal of Dermatology. Accepted Date: 19-Feb-2010.Ong P.Y., Ohtake T., Brandt C. et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347: 1151-1160.Gallo R.L., Murakami M., Ohtake T. et al. Biology and clinical relevance of naturally occurring antimicrobial peptides J Allergy Clin Immunol 2002; 110: 823-831.Niyonsaba F., Nagaoka I., Ogawa H. Human defensins and cathelicidins in the skin: beyond direct antimicrobial properties. Crit Rev Immunol 2006; 26: 545-576.Schroder J.M., Harder J. Antimicrobial skin peptides and proteins. Cell Mol Life Sci 2006; 63: 469-486.Niyonsaba F., Suzuki A., Ushio H. et al. The human antimicrobial peptide dermcidin activates normal human keratinocytes. British Journal of Dermatology 2009 Feb; 160(2): 243-9.Howell M.D., Novak N., Bieber T. et al. Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. J Invest Dermatol 2005; 125: 738-745.Niyonsaba F., Ushio H., Nakano N. et al. Antimicrobial peptides human b-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol 2007; 127: 594-604.Wood L.C., Elias P.M., Calhoun C. et al. Barrier disruption stimulates interleukin-1 alpha expression and release from a preformed pool in murine epidermis. J Invest Dermatol 1996; 106: 397-403.Caubet C., Jonca N., Bratssand M. et al. Degradation of corneodesmosome protein by two serine protease of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol 2004; 122: 1235-1244.Ekholm I.E., Bratssand M., Egelrud T. Stratum corneum tryptic enzyme in normal epidermis: a missing link in the desquamation process? J Invest Dermatol 2000; 114: 56-63.Suzuki Y., Nomura J., Koyama J. et al. The role of proteases in stratum corneum: involvement in stratum corneum desquamation. Arch Dermatol Res 1994; 286: 369-375.Taieb A., Hanifin J., Cooper K. et al. Proceedings of the 4th Georg Rajka International Symposium on Atopic Dermatitis, Arcachon, France, September 15-17, 2005. J Allergy Clin Immunol 2006: 117: 378-390.Taieb A. Hypothesis: from epidermal barrier dysfunction to atopic disorders. Contact Dermatitis 1999; 41: 177-180.Chamlin S.L., Kao J., Freiden I.J. et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002; 47: 198-208.Cork M.J., Robinson D.A., Vasilopoulos Y. et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol 2006; 118: 3-21.Ring J., Przybilla B., Ruzicka T., eds. Handbook of Atopic Eczema, 2nd edn., Springer, Heidelberg, 2006.Kawashima M., Hayashi N., Nogita T. et al. The usefulness of moisturizers for maintenance of remission in atopic dermatitis. Jpn J Dermatol 2007; 117: 1139-1145.Furue M., Furukawa F., Hide M. et al. Guidelines for therapy for atopic dermatitis 2004. Jpn J Dermatol 2004; 114: 135-142.Rawlings A.V., Harding C.R. Moisturization and skin barrier function Dermatol. Ther 2004; 17 (Suppl 1): 43-48.Levi K., Kwan A., Rhines A.S. et al. Emollient molecule effects on the drying stresses in human stratum corneum. British Association of Dermatologists 2010; 163: 695-703.Long C., Mills C., Finlay A. A practical guide to topical therapy in children Br J Dermatol 1998; 138: 293-296.Chamlin S.L., Kao J., Freiden I.J. et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002; 47: 198-208.